First Allied Advisory Services INC Increases Holding in Gilead Sciences INC (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment decreased to 0.75 in 2018 Q2. Its down 0.13, from 0.88 in 2018Q1. It dropped, as 75 investors sold GILD shares while 532 reduced holdings. 89 funds opened positions while 366 raised stakes. 977.84 million shares or 0.14% more from 976.44 million shares in 2018Q1 were reported. Homrich Berg has invested 0.02% in Gilead Sciences, Inc. (NASDAQ:GILD). Symphony Asset Limited Liability Corporation has invested 0.34% in Gilead Sciences, Inc. (NASDAQ:GILD). 78,682 are owned by Regions Fincl. Sky Investment Grp Inc Limited stated it has 16,882 shares or 0.48% of all its holdings. First City Capital Mgmt invested in 9,527 shares or 0.48% of the stock. Moreover, Portland Global Advsr Llc has 0.22% invested in Gilead Sciences, Inc. (NASDAQ:GILD). 3,194 are held by Carroll Finance Associates Inc. Signature owns 3,174 shares. Moreover, Liberty Mutual Asset Mngmt has 0.09% invested in Gilead Sciences, Inc. (NASDAQ:GILD). 267,547 are held by Commonwealth Bancorporation Of. First Foundation Advsrs reported 65,964 shares. Credit Suisse Ag reported 3.15M shares. Moreover, Lord Abbett has 0.09% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Norinchukin Bancorporation The invested in 0.23% or 214,534 shares. 682 were accumulated by Tradewinds Capital Limited Liability Company.

Since July 2, 2018, it had 0 insider buys, and 4 selling transactions for $14.63 million activity.

First Allied Advisory Services Inc increased its stake in Gilead Sciences Inc (GILD) by 81.2% based on its latest 2018Q2 regulatory filing with the SEC. First Allied Advisory Services Inc bought 68,614 shares as the company’s stock rose 3.76% with the market. The institutional investor held 153,111 shares of the health care company at the end of 2018Q2, valued at $10.84 million, up from 84,497 at the end of the previous reported quarter. First Allied Advisory Services Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $90.80B market cap company. The stock increased 0.92% or $0.64 during the last trading session, reaching $70.19. About 8.08M shares traded or 16.69% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 12.47% since December 7, 2017 and is downtrending. It has underperformed by 28.09% the S&P500.

First Allied Advisory Services Inc, which manages about $4.57B and $2.65B US Long portfolio, decreased its stake in Southern Co (NYSE:SO) by 104,589 shares to 51,807 shares, valued at $2.40 million in 2018Q2, according to the filing. It also reduced its holding in Vanguard Intl Equity Index F (VGK) by 79,642 shares in the quarter, leaving it with 25,983 shares, and cut its stake in Select Sector Spdr Tr (XLK).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: which released: “Gilead’s Vemlidy for chronic hepatitis B virus approved in China – Seeking Alpha” on November 19, 2018, also with their article: “After Hours Most Active for Nov 26, 2018 : CTL, GE, QQQ, RF, TEVA, HAL, BAC, INTC, AAPL, GILD, XEL, STLD – Nasdaq” published on November 26, 2018, published: “Gilead CAR-T therapy shows sustained benefit in treatment-resistant ALL patients – Seeking Alpha” on December 04, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: and their article: “Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know – Nasdaq” published on December 03, 2018 as well as‘s news article titled: “How The Parts Add Up: RNDV Targets $24 – Nasdaq” with publication date: November 29, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 5 analysts covering Gilead Sciences (NASDAQ:GILD), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Gilead Sciences has $94 highest and $75 lowest target. $85.50’s average target is 21.81% above currents $70.19 stock price. Gilead Sciences had 7 analyst reports since June 28, 2018 according to SRatingsIntel. The rating was downgraded by Robert W. Baird to “Neutral” on Thursday, July 26. Raymond James maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, October 26 with “Strong Buy” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, July 26. As per Friday, October 26, the company rating was downgraded by PiperJaffray. The rating was maintained by Cantor Fitzgerald on Friday, October 26 with “Overweight”.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.